Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxycycline
Drug ID BADD_D00725
Description Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline [FDA label]. This drug is a second-generation tetracycline, exhibiting lesser toxicity than first-generation tetracyclines [A174034]. Doxycycline may be used to treat a wide range of bacterial infections, depending on the results of antibiotic susceptibility testing.
Indications and Usage Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria. A complete list of organisms is available in the FDA label and in the "indications" section of this drug entry [FDA label]. The following are some of the major infections that may be treated with doxycycline [FDA label]: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (ornithosis) caused by Chlamydia psittaci Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis Nongonococcal urethritis caused by Ureaplasma urealyticum Relapsing fever due to Borrelia recurrentis **A note regarding anti-microbial resistance** It is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracyclines. Therefore, tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible [FDA label].
Marketing Status approved; investigational; vet_approved
ATC Code A01AB22; J01AA02
DrugBank ID DB00254
KEGG ID D00307; D07876
MeSH ID D004318
PubChem ID 54671203
TTD Drug ID D0S0LZ
NDC Product Code 23155-134; 50268-280; 63187-712; 67296-1368; 67296-1762; 68180-651; 71205-135; 71205-616; 71335-2100; 71335-2109; 76420-562; 59929-631; 69988-0020; 23155-135; 27808-233; 49884-726; 51407-678; 63323-130; 65841-823; 66794-237; 68382-911; 69238-1100; 0527-1338; 70518-1378; 70710-1122; 70710-1123; 72789-047; 0713-0572; 11014-0092; 0069-0970; 23155-136; 63187-135; 63187-936; 63304-130; 63304-616; 64380-206; 67296-1858; 68071-2761; 68083-481; 68382-706; 69238-1501; 0527-1335; 71335-1988; 71610-220; 62332-249; 62332-250; 63304-173; 64380-205; 67296-1385; 68999-417; 0527-1537; 70518-3488; 70934-996; 72189-006; 43386-792; 50090-5984; 55700-723; 0299-3822; 63187-672; 64380-179; 65841-821; 68071-2617; 68382-910; 70518-0038; 70518-3729; 70934-808; 71335-0861; 23155-133; 50268-281; 60687-716; 63629-8212; 68382-782; 69238-1500; 70771-1122; 71335-9608; 0713-0570; 0713-0571; 55488-0200; 40032-790; 46708-250; 51655-350; 62135-417; 67296-1570; 67296-1688; 67457-437; 68071-2152; 68180-652; 70518-3365; 70771-1007; 70771-1008; 70771-1009; 70934-499; 71335-2096; 0143-9381; 49884-727; 51655-711; 55700-122; 61919-276; 63304-131; 63304-614; 63629-7751; 64380-207; 0404-9855; 68071-2750; 68071-4354; 68180-650; 68382-707; 70518-0213; 70771-1121; 71335-1479; 72266-237; 16714-644; 40032-791; 43386-791; 60219-1100; 60687-344; 60760-721; 64380-180; 64380-181; 65841-822; 70710-1121; 70771-1006; 72789-199; 72789-258; 50909-8106; 40032-792; 43386-790; 46708-249; 49884-305; 50090-4833; 53002-0673; 53002-0674; 63304-132; 63304-615; 64380-208; 66993-815; 67296-1025; 68084-743; 68180-657; 68308-668; 0527-1535; 70518-0187; 70710-1124; 71205-385; 72789-308; 47621-017; 55018-164; 50090-5983; 51407-387
UNII N12000U13O
Synonyms Doxycycline | Doxycycline Monohydrate | Vibramycin | Atridox | Doxycycline Phosphate (1:1) | BMY-28689 | BMY 28689 | BMY28689 | BU-3839T | BU 3839T | BU3839T | Doryx | Doxycycline Calcium Salt (1:2) | Doxycycline Hyclate | Doxycycline Hemiethanolate | Doxycycline Monohydrochloride, 6-epimer | Doxycycline Monohydrochloride, 6 epimer | Doxycycline Monohydrochloride, Dihydrate | Doxycycline Calcium | 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))- | Alpha-6-Deoxyoxytetracycline | Alpha 6 Deoxyoxytetracycline | Doxycycline-Chinoin | Doxycycline Chinoin | Hydramycin | Oracea | Periostat | Vibra-Tabs | Vibra Tabs | Vibramycin Novum | Vibravenos
Chemical Information
Molecular Formula C22H24N2O8
CAS Registry Number 564-25-0
SMILES CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Laryngeal pain22.12.03.010--
Leukopenia01.02.02.001---
Lip swelling07.05.04.005; 10.01.05.005; 23.04.01.0070.000033%-
Loss of consciousness17.02.04.004---
Lymphadenopathy01.09.01.002---
Malaise08.01.01.0030.000093%
Mass08.03.05.003---
Memory impairment17.03.02.003; 19.20.01.003--
Muscle spasms15.05.03.0040.000022%
Muscular weakness15.05.06.001; 17.05.03.005--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.0010.000033%
Nail discolouration23.02.05.001--
Nasal congestion22.04.04.001--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.0010.000120%
Neck pain15.03.04.009--
Nephropathy toxic12.03.01.010; 20.05.03.002---
Neuropathy peripheral17.09.03.0030.000049%-
Neutropenia01.02.03.004---
Night sweats08.01.03.031; 23.02.03.006---
Odynophagia07.01.06.036---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Oesophageal pain07.01.05.012--
Oesophageal ulcer07.04.05.0020.000086%
Oesophagitis07.08.05.0010.000060%
Onycholysis23.02.05.004---
Oral pain07.05.05.034--
Pain08.01.08.004--
Pain in jaw15.02.01.003---
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene